$INTI
Inhibitor Therapeutics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000119312516680021 Filed on August 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.010M $720.0K $490.0K
YoY Change 68.33% 46.94% 157.89%
% of Gross Profit
Research & Development $720.3K $605.5K $300.3K
YoY Change 19.72% 101.65% -84.44%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.734M $1.330M $791.7K
YoY Change 44.27% 68.01% -62.58%
Operating Profit -$1.734M -$1.330M -$791.7K
YoY Change 44.27% 68.01% -62.58%
Interest Expense $10.00K $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.730M -$1.330M -$790.0K
YoY Change 44.17% 68.35% -63.08%
Income Tax
% Of Pretax Income
Net Earnings -$1.725M -$1.329M -$791.7K
YoY Change 43.5% 67.88% -63.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 300.4M shares 268.4M shares 211.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.550M $4.620M $1.890M
YoY Change 186.29% 144.44% 600.0%
Cash & Equivalents $3.554M $4.615M $1.894M
Short-Term Investments
Other Short-Term Assets $58.90K $50.22K $50.00K
YoY Change -1.83% 0.44% 70.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.613M $4.665M $1.940M
YoY Change 177.93% 140.5% 545.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $250.0K $250.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $250.0K $250.0K $250.0K
YoY Change 0.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $3.613M $4.665M $1.940M
Total Long-Term Assets $250.0K $250.0K $250.0K
Total Assets $3.863M $4.915M $2.190M
YoY Change 149.23% 124.46% 628.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $441.5K $396.0K $246.5K
YoY Change -0.14% 60.69% -12.03%
Accrued Expenses $103.0K
YoY Change 415.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $469.6K $618.1K $412.7K
YoY Change -13.1% 49.77% -9.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $469.6K $618.1K $412.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $469.6K $618.1K $412.7K
YoY Change -13.1% 49.77% -8.29%
SHAREHOLDERS EQUITY
Retained Earnings -$40.42M -$38.70M -$33.94M
YoY Change 15.03% 14.02% 10.96%
Common Stock $43.81M $42.99M $35.71M
YoY Change 21.2% 20.38% 862151.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.393M $4.297M $1.777M
YoY Change
Total Liabilities & Shareholders Equity $3.863M $4.915M $2.190M
YoY Change 149.23% 124.46% 628.69%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$1.725M -$1.329M -$791.7K
YoY Change 43.5% 67.88% -63.02%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.060M -$1.010M -$690.0K
YoY Change 63.08% 46.38% 137.93%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.500M 2.500M
YoY Change 120.0% 346.43%
NET CHANGE
Cash From Operating Activities -1.060M -1.010M -690.0K
Cash From Investing Activities
Cash From Financing Activities 0.000 5.500M 2.500M
Net Change In Cash -1.060M 4.490M 1.810M
YoY Change 63.08% 148.07% 570.37%
FREE CASH FLOW
Cash From Operating Activities -$1.060M -$1.010M -$690.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
300353270 shares
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1893572
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
300353270 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
300353270 shares
CY2016Q2 us-gaap Assets
Assets
4915294
CY2016Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4100000
CY2016Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
4665294
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42963198
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4615073
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
30035
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
396047
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
50221
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
222023
CY2016Q2 us-gaap Liabilities
Liabilities
618070
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4915294
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
618070
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
4297224
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38696009
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2015Q4 us-gaap Assets
Assets
885859
CY2015Q4 us-gaap Assets Current
AssetsCurrent
635859
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36571982
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
383356
CY2015Q4 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
52500
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
34414
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78524
CY2015Q4 us-gaap Liabilities
Liabilities
461880
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
885859
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
461880
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
423979
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36172538
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1528411
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1101025
us-gaap Revenues
Revenues
0
us-gaap Operating Expenses
OperatingExpenses
1714330
us-gaap Net Income Loss
NetIncomeLoss
-1714330
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
101792
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
198457
us-gaap Operating Income Loss
OperatingIncomeLoss
-1714330
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-971589
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
613305
us-gaap Share Based Compensation
ShareBasedCompensation
839406
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
219668924 shares
hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
90000
hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2500000
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
895392
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4013628
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1336491
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Revenues
Revenues
0
us-gaap Operating Expenses
OperatingExpenses
2524524
us-gaap Net Income Loss
NetIncomeLoss
-2523471
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
156190
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15807
us-gaap Operating Income Loss
OperatingIncomeLoss
-2524524
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1053
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5501324
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1487696
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2664900
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2664900
dei Trading Symbol
TradingSymbol
HPPI
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1188033
us-gaap Share Based Compensation
ShareBasedCompensation
895392
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
260647569 shares
hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
2836424
hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2836424
CY2016Q2 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
25000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
491368
CY2015Q2 us-gaap Revenues
Revenues
0
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
791656
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-791656
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-791656
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
300288
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
227827263 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
724539
CY2016Q2 us-gaap Revenues
Revenues
0
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
1330059
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-1329006
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1330059
CY2016Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1053
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
605520
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
275941869 shares

Files In Submission

Name View Source Status
0001193125-16-680021-index-headers.html Edgar Link pending
0001193125-16-680021-index.html Edgar Link pending
0001193125-16-680021.txt Edgar Link pending
0001193125-16-680021-xbrl.zip Edgar Link pending
d199796d10q.htm Edgar Link pending
d199796dex311.htm Edgar Link pending
d199796dex312.htm Edgar Link pending
d199796dex321.htm Edgar Link pending
d199796dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20160630.xml Edgar Link completed
hppi-20160630.xsd Edgar Link pending
hppi-20160630_cal.xml Edgar Link unprocessable
hppi-20160630_def.xml Edgar Link unprocessable
hppi-20160630_lab.xml Edgar Link unprocessable
hppi-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending